Other substances

Fluvoxamine

A trifluoromethylbenzene selective serotonin reuptake inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
13
 AI-suggested references
9
 Clinical trials

General information

Fluvoxamine is a selective serotonin reuptake inhibitor with antidepressant, anxiolytic and anti-obsessive-compulsive properties (NCIt).

The TOGETHER trial data show that fluvoxamine reduces the rate of COVID-19-related hospitalization among high-risk patients (Reis et al., 2022).

Fluvoxamine on DrugBank
Fluvoxamine on PubChem
Fluvoxamine on Wikipedia


Marketed as

DUMIROX; FAVERIN; FEVARIN; FLOXYFRAL; FLUVOXAMINE MALEATE; LUVOX; MAVERAL

 

Structure image - Fluvoxamine

COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Small molecule Randomized controlled double-blind trial Mild severity 		Patients 45.54

No case of clinical deterioration in the treatment group (statistically significant). Sample size: 80 + 72 placebo (at randomization). Dosage: 50 mg on day 1; 100 mg twice daily on days 2 and 3; 100 mg 3 times daily on days 4-15. Endpoint: Clinical deterioration within 15 days of randomization (primary).


 Nov/12/2020
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Small molecule Randomized controlled double-blind trial 		Patients at risk of disease progression 26.76

Hospitalization was less frequent among the patients in the treatment group compared to the placebo group. Sample size: 548 (per-protocol) + 619 (per-protocol) placebo + 1826 other treatment groups. Dosage: 100 mg twice a day for 10 days. Main outcome: Hospitalization assessed up to 28 days post randomization.

 Oct/27/2021

AI-suggested references

Link Publication date
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
May/15/2021
Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?
Nov/10/2021
Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid.
Aug/10/2021
Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention.
Oct/17/2021
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls
Dec/01/2021
The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.
Apr/05/2021
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Nov/01/2021
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Feb/01/2021
Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort.
Mar/03/2021
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Nov/12/2020
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.
Jan/05/2021
Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants
Feb/11/2022
Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective
Apr/01/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04668950 Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) Completed Phase 3 Dec/22/2020 Sep/28/2021
  • Alternative id - 202011101
  • Interventions - Drug: Fluvoxamine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Northwestern University, Chicago, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson, Seattle, Washington, United States|McGill University Health Center, Montreal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 683
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical deterioration|Post Covid Functioning
NCT05216614 Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia Withdrawn Phase 2 Dec/14/2021 Feb/22/2022
  • Alternative id - 202111124
  • Interventions - Drug: Fluvoxamine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Washington University, Saint Louis, Missouri, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Clinical Global Impression Scale (CGI)|University of Pennsylvania Smell Identification Test (UPSIT)|Olfactory Dysfunction Outcomes Rating (ODOR)|The Depression, Anxiety and Stress Scale - 21 Items (DASS-21)|The Smell Catastrophizing Scale (SCS)|36-Item Short Form Health Survey (SF-36)
NCT04711863 Fluvoxamine for Adults With Mild to Moderate COVID-19 Suspended Phase 2 Jan/16/2021 Jul/31/2021
  • Alternative id - S2020-3124-0001
  • Interventions - Drug: Fluvoxamine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Asan Medical Center, Seoul, Korea, Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Clinical deterioration|Time to clinical deterioration|Rate of each component of primary outcome including WHO Clinical Progression Scale|Rate of transfer to general hospital regardless of any reasons|Evaluation of adverse events
NCT04718480 Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients Recruiting Phase 2 Nov/27/2020 Dec/01/2022
  • Alternative id - SD-COVID19-01|2020-002299-11
  • Interventions - Drug: Placebo|Drug: Fluvoxamine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Dél-pesti Centrumkórház, Budapest, Hungary|Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|Országos Korányi Pulmonológiai Intézet, Budapest, Hungary|Debreceni Egyetem Kenézy Gyula Kórház Infektológia, Debrecen, Hungary
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Time to clinical recovery after treatment
NCT04342663 A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Completed Phase 2 Apr/10/2020 Dec/12/2020
  • Alternative id - 202004023
  • Interventions - Drug: Fluvoxamine|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 152
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants Who Met Clinical Worsening|Clinical Deterioration on a Likert-type Scale (0-6)
NCT04885530 ACTIV-6: COVID-19 Study of Repurposed Medications Recruiting Phase 3 Jun/08/2021 Mar/01/2023
  • Alternative id - Pro00107921|3U24TR001608-05W1
  • Interventions - Drug: Ivermectin|Drug: Fluvoxamine|Drug: Fluticasone|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lamb Health, LLC, Gilbert, Arizona, United States|First Care Medical Clinic, Mesa, Arizona, United States|Trident Health Center, Peoria, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Assuta Family Medical Group APMC, North Hollywood, California, United States|Doctors Medical Group of Colorado Springs, P.C., Colorado Springs, Colorado, United States|Pine Ridge Family Medicine Inc., Colorado Springs, Colorado, United States|Tabitha B. Fortt, M.D., LLC, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Lupus Foundation of Gainesville, Gainesville, Florida, United States|University of Florida Health, Gainesville, Florida, United States|University of Florida-JAX-ASCENT, Jacksonville, Florida, United States|Sunshine Walk In Clinic, Lake Mary, Florida, United States|Lakeland Regional Medical Center, Lakeland, Florida, United States|University of Miami, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Innovation Clinical Trials Inc., Palmetto Bay, Florida, United States|Lice Source Services Plantation, Plantation, Florida, United States|Premier Health, Saint Petersburg, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|UF Health Precision Health Research, The Villages, Florida, United States|Emory Healthcare, Atlanta, Georgia, United States|Essential Medical Care, Inc., College Park, Georgia, United States|David Kavtaradze MD, Inc., Cordele, Georgia, United States|Elite Family Practice, Douglasville, Georgia, United States|Christ the King Health Care, P.C., Loganville, Georgia, United States|Miller Family Practice, LLC, Macon, Georgia, United States|Olivo Wellness Medical Center, Chicago, Illinois, United States|NorthShore Medical Group, Evanston, Illinois, United States|Advanced Medical Care, Ltd, Lake Zurich, Illinois, United States|Franciscan Health Michigan City, Michigan City, Indiana, United States|Del Pilar Medical and Urgent Care, Mishawaka, Indiana, United States|University of Kansas - Wichita, Wichita, Kansas, United States|A New Start II, LLC, Central City, Kentucky, United States|University Medical Center- New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Jadestone Clinical Research, LLC, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Health Quality Primary Care, Lawrence, Massachusetts, United States|Ananda Medical Clinic, Dearborn, Michigan, United States|GFC of Southeastern Michigan, PC, Detroit, Michigan, United States|Romancare Health Services, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Missouri - Columbia, Columbia, Missouri, United States|Focus Clinical Research Solutions, Bayonne, New Jersey, United States|Raritan Bay Primary Care & Cardiology Associates, Matawan, New Jersey, United States|Mediversity Healthcare, Turnersville, New Jersey, United States|Geriatrics and Medical Associates, Clinton, New York, United States|Weill Cornell Medical College, New York, New York, United States|Spinal Pain and Medical Rehab, PC, Yonkers, New York, United States|Vaidya MD PLLC, Clayton, North Carolina, United States|Maria Medical Center, PLLC, Dunn, North Carolina, United States|Duke Clinical Research Institute, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|TriHealth, Inc, Montgomery, Ohio, United States|The Heart and Medical Center, Durant, Oklahoma, United States|Hugo Medical clinic, Hugo, Oklahoma, United States|Temple University Medical Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical Trials Center of Middle TN, Franklin, Tennessee, United States|Rapha Family Wellness, Hendersonville, Tennessee, United States|Medical Specialists of Knoxville, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Express Family Clinic, Allen, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Family Practice Doctors P.A., Humble, Texas, United States|University Diagnostics and Treatment Clinic, Pasadena, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 15000
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of hospitalizations as measured by patient reports.|Number of deaths as measured by patient reports|Number of symptoms as measured by patient reports|Change in COVID Clinical Progression Scale|Number of hospitalizations as measured by patient reports|Number of Symptom Resolutions as measured by patient reports|Change in Quality of Life (QOL) as measured by the PROMIS-29|Composite score of hospitalizations, urgent care visits, and emergency room visits as measured by patient reports
NCT05087381 Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community Recruiting Phase 4 Oct/01/2021 Apr/30/2022
  • Alternative id - 64197
  • Interventions - Drug: FluvoxaMINE Maleate 50 MG|Combination Product: Fluvoxamine, Bromhexine|Combination Product: Fluvoxamine, Cyproheptadine|Drug: Niclosamide Pill|Combination Product: Niclosamide, Bromhexine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Rajvithi Hospital, Ratchathewi, Bangkok, Thailand|Chiangmai Neurological Hospital, Chiangmai, Thailand
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital admission or mortality related to COVID-19|Time taken to self- report recovery|Progression to severe COVID-19 Disease|Reduction (change) in GI viral shedding (by PCR)|Change in respiratory viral clearance (by PCR)|Time to resolution of a fever|Negative effects on well being
NCT04510194 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Active, not recruiting Phase 3 Jan/01/2021 Feb/01/2023
  • Alternative id - GIM-2020-29324
  • Interventions - Drug: Metformin|Drug: Placebo|Drug: Fluvoxamine|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Olive View UCLA Medical Center, Sylmar, California, United States|University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center, Aurora, Colorado, United States|New West Physicians, Golden, Colorado, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|American Health Network of Indiana, Greenfield, Indiana, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1350
  • Age - 30 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Clinical Progression|Maximum symptom severity|Clinical Progression Scale|Time to meaningful recovery|Laboratory Outcome Subsidy - Viral Load|Laboratory Outcome Subsidy|Laboratory Outcome Subsidy - Microbiome|Portion of participants with Post-Acute Sequelae of SARS-CoV-2 infection (PASC)
NCT04727424 Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms Recruiting Phase 3 Jan/19/2021 Nov/01/2023
  • Alternative id - TOGETHER_2
  • Interventions - Drug: Fluvoxamine Maleate 100 MG [Luvox]|Drug: Budesonide Powder|Drug: Placebo (mild disease)|Drug: Peginterferon Lambda-1a|Drug: Placebo (SpO2 < 94%)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - City of Betim, Betim, MG, Brazil|Hospital e Maternidade Santa Rita, Contagem, MG, Brazil|City of Governador Valadares, Governador Valadares, MG, Brazil|City of Ibirité, Ibirité, MG, Brazil|City of Nova Lima, Nova Lima, MG, Brazil|City of Santa Luzia, Santa Luzia, MG, Brazil|City of Sete Lagoas, Sete Lagoas, MG, Brazil|CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|City of Brumadinho, Brumadinho, Minas Gerais, Brazil|City of Igarapé, Igarapé, Minas Gerais, Brazil|Centro Universitário FIPMOC, Montes Claros, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 4669
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of fluvoxamine + budesonide, peginterferon Lambda and fluvoxamine in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19;|Rate of fluvoxamine + budesonide, peginterferon Lambda and fluvoxamine in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)|Change in viral load on day 03 and 07 after randomization (interferon lambda arm)|Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms)|Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19 or associated complications.|Number of days with respiratory symptoms since randomization|Rate of all-cause hospitalizations|Rate of COVID-19 related hospitalizations|Number of days on Mechanical Ventilator|Number of Days on Intensive Care Unit|Number of days on hospitalizations|Health and Functioning after COVID-19 disease|WHO ordinal scale for clinical improvement|Number of days on respiratory Symptoms|Adherence of Study drug
Export (.csv)